News und Analysen

CI Global Asset Management (“CI GAM”) today launches the CI Asset Allocation ETFs, a suite of low-cost all-in-one portfolio solutions. The six ETFs, which begin trading today on the Toronto Stock

CI Financial Corp. (“CI” or the “Offeror”) (TSX: CIX) announced today the final pricing of its tender offers to purchase for cash, in three separate offers (the “Offers”), a targeted aggregate

Granite Real Estate Investment Trust and Granite REIT Inc. (TSX: GRT.UN / NYSE: GRP.U) (“Granite REIT” and “Granite GP”, and collectively, “Granite”) today announced the acceptance by the Toronto

On May 11, 2023 CI Financial Corp. (“CI” or the “Offeror”) (TSX: CIX) announced that it was offering to purchase for cash, in three separate offers (the “Offers”), a targeted aggregate principal

Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.2667 per stapled unit for the month of

CI Global Asset Management (“CI GAM”) today announced the launch of a liquid alternatives mutual fund series that provides exposure to a diverse portfolio of commodities in the energy, metals and

CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the month ending May 31, 2023 in respect of the CI ETFs. In all cases, the distribution will be paid on

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2023.

CI Financial Corp. (“CI”) (TSX: CIX) today released financial results for the quarter ended March 31, 2023.

CI also announced this morning that it has agreed to sell a 20% minority stake in its

CI Financial Corp. (“CI”) (TSX: CIX) announced today that it has agreed to sell a 20% minority investment in its U.S. wealth management business (“CI US”) to a diversified group of leading

CI Financial Corp. (“CI” or the “Offeror”) (TSX: CIX) today announced that it is offering to purchase for cash, in three separate offers (the “Offers”), a targeted aggregate principal amount of up

Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control, and water treatment in utility and

CI Financial Corp. (“CI”) (TSX: CIX) announced today it has reached an agreement to sell its minority stake in Congress Wealth Management, LLC (“Congress”) to Audax Private Equity.

Congress, led

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system

Regulatory News:

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented two additional posters reporting the latest research updates on CLEC-1 (new myeloid immune checkpoint), from

Mannatech, Incorporated (NASDAQ: MTEX), announced the formation of a new wholly owned subsidiary that will serve as its innovation hub. After many months of study and exploration, this subsidiary

Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and

CI Financial Corp. (“CI”) (TSX: CIX) today reported preliminary total assets of $391.1 billion as at March 31, 2023, consisting of asset management assets of $122.0 billion, Canadian wealth

Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.2667 per stapled unit for the month of

Regulatory News:

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces three presentations at the American Association for Cancer Research (AACR) Annual Meeting in Orlando

Regulatory News:

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2022 and provided an update on key clinical and